TB-500
TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide corresponding to the active domain of thymosin beta-4 (Ac-LKKTETQ). Preclinical studies in cell cultures and animal models indicate that TB-500 promotes cell migration, angiogenesis, actin sequestration, and tissue repair processes, supporting wound healing and regeneration in various injury models.[1][2]
Key Research Areas
- Wound Healing & Tissue Regeneration – In rodent dermal and corneal wound models, TB-500 has been shown to accelerate epithelialization, increase angiogenesis, and enhance dermal matrix remodeling.[3][4]
- Actin Regulation & Cell Motility – Preclinical investigations demonstrate TB-500 binds to actin monomers, promotes cell migration and proliferation in fibroblasts and endothelial cells, and supports cytoskeletal dynamics in repair processes.[5][6]
- Anti-Inflammatory & Protective Pathways – Animal studies suggest TB-500 reduces inflammatory cell infiltration, modulates cytokine profiles, and protects against tissue damage in models of myocardial infarction, spinal cord injury, and dry eye.[7][8]
Product Specifications
| CAS Number |
77591-33-4 |
| Molecular Formula |
C212H350N56O78S |
| Molar Mass |
4963.50 g/mol |
| Sequence |
Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser |
| Synonyms |
Thymosin Beta-4, TB4, LKKTETQ fragment (active domain) |
| Purity |
≥99% (HPLC) |
| Form |
Lyophilized powder |
| Storage |
−20°C (long-term), 2–8°C (reconstituted) |
| Solubility |
Bacteriostatic water or sterile saline for reconstitution |
References
- 1. Sosne G, et al. Thymosin beta 4: potential to treat corneal and dermal wounds. Ann N Y Acad Sci. 2010. PubMed
- 2. Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. PubMed
- 3. Smart N, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 2007. PubMed
- 4. Sosne G, et al. Thymosin beta4 promotes corneal wound healing and decreases inflammation in vivo. Exp Eye Res. 2005. PubMed
- 5. Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005. PubMed
- 6. Crockford D, et al. Thymosin beta4 and angiogenesis: modes of action and therapeutic potential. Ann N Y Acad Sci. 2007. PubMed
- 7. Xiong Y, et al. Thymosin beta4 improves neurological outcome after traumatic brain injury in mice. Neurobiol Dis. 2012. PubMed
- 8. Zhang J, et al. Thymosin beta4 reduces myocardial infarct size and improves cardiac function in rats. J Mol Cell Cardiol. 2009. PubMed
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.
